About Us
Making a difference, patient by patient
US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs.
Patients are key to everything that we do at US WorldMeds

Vision
We will remain a sustainable, privately held specialty pharmaceutical company.

Mission
We will develop, license, and market meaningful and accessible healthcare products that improve lives and result in a thriving community of patients, employees, and shareholders.

Values
![]() ![]() ![]() ![]() ![]() |
QUICK ACCESS TO THE LATEST COMPANY NEWS
Discover the latest news, featured stories, and past news from US WorldMeds
March 31, 2022US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone ProductHigh-Dose Naloxone Now Available to Help Combat the Growing Epidemic of Overdose DeathsLOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and availability of ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL. ZIMHI is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose as emergency therapy in settings where opioids may be present. Read more |